|
Orozco-Beltran D, Merino-Torres JF, Perez A, Cebrian-Cuenca AM, Parraga-Martinez I, Avila-Lachica L, Rojo-Martinez G, Pomares-Gomez FJ, Alvarez-Guisasola F, Sanchez-Molla M, Gutierrez F, Ortega FJ, Mata-Cases M, Carretero-Anibarro E, Vilaseca JM, Quesada JA. Diabetes Does Not Increase the Risk of Hospitalization Due to COVID-19 in Patients Aged 50 Years or Older in Primary Care-APHOSDIAB-COVID-19 Multicenter Study. J Clin Med. 2022 Apr 8;11(8):2092. doi: 10.3390/jcm11082092. PubMed PMID: 35456185; PubMed Central PMCID: PMC9025638.
AÑO: 2022; IF: 4.964
|
35456185
|
Orozco-Beltran D, Brotons Cuixart C, Banegas Banegas JR, Gil Guillen VF, Cebrian Cuenca AM, Martin Rioboo E, Jorda Baldo A, Vicuna J, Navarro Perez J. [Cardiovascular preventive recommendations. PAPPS 2022 thematic updates. Working groups of the PAPPS]. Aten Primaria. 2022 Oct;54 Suppl 1(Suppl 1):102444. doi: 10.1016/j.aprim.2022.102444. Spanish. PubMed PMID: 36435583; PubMed Central PMCID: PMC9705225.
AÑO: 2022; IF: 2.5
|
|
Cebrian-Cuenca AM, Mata-Cases M, Franch-Nadal J, Mauricio D, Orozco-Beltran D, Consuegra-Sanchez L. Half of patients with type 2 diabetes mellitus are at very high cardiovascular risk according to the ESC/EASD: data from a large Mediterranean population. Eur J Prev Cardiol. 2022 Feb 9;28(18):e32-e34. doi: 10.1093/eurjpc/zwaa073. No abstract available. PubMed PMID: 33733654.
AÑO: 2022; IF: 8.3
|
|
Gorgojo-Martinez JJ, Mezquita-Raya P, Carretero-Gomez J, Castro A, Cebrian-Cuenca A, de Torres-Sanchez A, Garcia-de-Lucas MD, Nunez J, Obaya JC, Soler MJ, Gorriz JL, Rubio-Herrera MA. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2022 Dec 24;12(1):145. doi: 10.3390/jcm12010145. PubMed PMID: 36614945; PubMed Central PMCID: PMC9821052.
AÑO: 2022; IF: 4.964
|
|
Romera I, Artime E, Ihle K, Diaz-Cerezo S, Rubio de-Santos M, de Prado A, Cebrian-Cuenca A, Conget I. A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study. Adv Ther. 2022 Aug;39(8):3589-3601. doi: 10.1007/s12325-022-02196-0. Epub 2022 Jun 11. PubMed PMID: 35689162.
AÑO: 2022; IF: 3.8
|